Neurogene Inc.
NGNEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNeurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The $435.2M market capitalization puts NGNE squarely in small-cap range for its industry. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Market Cap
$435.2M
Beta
2.08
P/E (TTM)
—
P/E (Fwd)
-4.93
EPS (TTM)
$-4.55
EPS (Fwd)
$-5.59
ROE
-37.3%
ROA
-23.9%
Cash
$243.2M
Total Debt
$9.1M
Free CF
-$47.8M
52W Change
34.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $243.2M in cash comfortably exceeding the $9.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$47.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -37.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 2.08 means NGNE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, NGNE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NGNE.